2001Unpublished venueRequires access

Die Down-Regulation von FAS (APO-l/CD95) begiinstigt die Metastasierung beim Osophaguskarzinom Down regulation of Fas (AP01ICD9S) seems to promote metastasis in esophageal cancer

P. Scheunemann, Stefan B. Hosch, S. Sudmann, NH Stoecklein, W. T. Knoefel, Jacob R. Izbicki, Universitats-Krankenhaus Hamburg-Eppendorf

Open publisher page 0 citations

Abstract

The cell surface receptor Fas (APO-1/CD95) mediates apoptosis via interaction with its li­ gand (FasL). Fas is normally expressed in a variety of adult tissues including epithelial tis­ sue, whereas FasL expression is predominantly restricted to cells of the immune system or immunoprivileged tissues. In tumors, modulation of Fas and FasL expression is fre­ quent. There is evidence that tumors may escape from immune surveillance via downreg­ ulation of Fas or expression of soluble FasL. Furthermore, upregulation of FasL on cells may induce apoptosis in infiltrating cytotoxic T-cells (counter attack model). So far, little is known about the role of Fas and FasL expression in the progression of esophageal carcinoma. We therefore analyzed cytostat sections of 70 esophageal carcino­ mas with tumor-free resection margins (Ro) for Fas and FasL expression immunohisto­ chemically with the ABC technique using the monoclonal anti-Fas antibody DX2 (Pharm­ ingen) and the polyclonal anti-FasL antibody Q20 (Santa Cruz Biotech.). Stained sections were evaluated semiquantitatively. Staining intensity was also taken into account. In total, 49 of 70 (70%) tumors showed downregulation of Fas, whereas upregulation of FasL was observed in 55 of 70 (79%) cases. Correlation of Fas data with nodal micro dissemination status revealed that patients with Fas downregulation of their primary tumors showed isolated cells in apparently tumor free lymph nodes more frequently than pa­ tients with normal Fas expression (60% vs. 23%; P = 0.01). Moreover, 46% of patients with Fas downregulation developed metastatic relapse within a mean time of 33 month com­ pared to 8% of patients with normal Fas expression within a mean time of 68 months (p = 0.026). In conclusion, modulations of Fas and FasL expression are frequent events in esophageal carcinoma. Furthermore, downregulation of Fas seems to playa role in cell dissemination and/or establishment of metastases in secondary organs via mediation of apoptotic resistance.

About this research paper

What this paper is about

The cell surface receptor Fas (APO-1/CD95) mediates apoptosis via interaction with its li­ gand (FasL). Fas is normally expressed in a variety of adult tissues including epithelial tis­ sue, whereas FasL expression is predominantly restricted to cells of the immune system or immunoprivileged tissues. In tumors, modulation of Fas and FasL expression is fre­ quent. There is evidence that tumors may escape from immune surveillance via downreg­ ulation of Fas or expression of soluble FasL. Furthermore, upregulation of FasL on cells may induce apoptosis in infiltrating cytotoxic T-cells (counter attack model). So far, little is known about the role of Fas and FasL expression in the progression of esophageal carcinoma. We therefore analyzed cytostat sections of 70 esophageal carcino­ mas with tumor-free resection margins (Ro) for Fas and FasL expression immunohisto­ chemically with the ABC technique using the monoclonal anti-Fas antibody DX2 (Pharm­ ingen) and the polyclonal anti-FasL antibody Q20 (Santa Cruz Biotech.). Stained sections were evaluated semiquantitatively. Staining intensity was also taken into account. In total, 49 of 70 (70%) tumors showed downregulation of Fas, whereas upregulation of FasL was observed in 55 of 70 (79%) cases. Correlation of Fas data with nodal micro dissemination status revealed that patients with Fas downregulation of their primary tumors showed isolated cells in apparently tumor free lymph nodes more frequently than pa­ tients with normal Fas expression (60% vs. 23%; P = 0.01). Moreover, 46% of patients with Fas downregulation developed metastatic relapse within a mean time of 33 month com­ pared to 8% of patients with normal Fas expression within a mean time of 68 months (p = 0.026). In conclusion, modulations of Fas and FasL expression are frequent events in esophageal carcinoma. Furthermore, downregulation of Fas seems to playa role in cell dissemination and/or establishment of metastases in secondary organs via mediation of apoptotic resistance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The cell surface receptor Fas (APO-1/CD95) mediates apoptosis via interaction with its li­ gand (FasL). Fas is normally expressed in a variety of adult tissues including epithelial tis­ sue, whereas FasL expression is predominantly restricted to cells of the immune system or immunoprivileged tissues. In tumors, modulation of Fas and FasL expression is fre­ quent. There is evidence that tumors may escape from immune surveillance via downreg­ ulation of Fas or expression of soluble FasL. Furthermore, upregulation of FasL on cells may induce apoptosis in infiltrating cytotoxic T-cells (counter attack model). So far, little is known about the role of Fas and FasL expression in the progression of esophageal carcinoma. We therefore analyzed cytostat sections of 70 esophageal carcino­ mas with tumor-free resection margins (Ro) for Fas and FasL expression immunohisto­ chemically with the ABC technique using the monoclonal anti-Fas antibody DX2 (Pharm­ ingen) and the polyclonal anti-FasL antibody Q20 (Santa Cruz Biotech.). Stained sections were evaluated semiquantitatively. Staining intensity was also taken into account. In total, 49 of 70 (70%) tumors showed downregulation of Fas, whereas upregulation of FasL was observed in 55 of 70 (79%) cases. Correlation of Fas data with nodal micro dissemination status revealed that patients with Fas downregulation of their primary tumors showed isolated cells in apparently tumor free lymph nodes more frequently than pa­ tients with normal Fas expression (60% vs. 23%; P = 0.01). Moreover, 46% of patients with Fas downregulation developed metastatic relapse within a mean time of 33 month com­ pared to 8% of patients with normal Fas expression within a mean time of 68 months (p = 0.026). In conclusion, modulations of Fas and FasL expression are frequent events in esophageal carcinoma. Furthermore, downregulation of Fas seems to playa role in cell dissemination and/or establishment of metastases in secondary organs via mediation of apoptotic resistance.

Key concepts: Fas ligand, Downregulation and upregulation, Fas receptor, Apoptosis, Cancer research, Immune system, Medicine, Cytotoxic T cell

Related papers

Back to paper searchBrowse research topicsOriginal source
Die Down-Regulation von FAS (APO-l/CD95) begiinstigt die Metastasierung beim Osophaguskarzinom Down regulation of Fas (AP01ICD9S) seems to promote metastasis in esophageal cancer — Research Paper | ScholarLens